Observational studyRespiratory research2025
Antiphospholipid antibodies and subclinical interstitial lung disease in the MESA cohort.
Observational study in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundInterstitial lung disease (ILD) is a rare complication of antiphospholipid syndrome (APS), but circulating antiphospholipid antibodies have been detected in patients with ILD without APS. Whether antiphospholipid antibodies are associated with subclinical ILD phenotypes is unknown. We aim to examine the associations between anticardiolipin (aCL) and B-2 glycoprotein-1 (B2GP1) isotypes and high attenuation areas (HAA) and interstitial lung abnormalities (ILA) on CT scans in the Multi-Ethnic Study of Atherosclerosis (MESA).
methodsWe measured serum aCL and B2GP1 isotypes and calculated proportion of HAA on cardiac CT scan in 6623 MESA participants at baseline. The presence of ILAs were assessed on full lung CT scans at Exam 5. We used linear and logistic regression to examine these associations. We examined interactions by age, race, and smoking status.
resultsIn adjusted models, every doubling of aCL IgA, IgG, and IgM was associated with 0.36% (95% CI 0.03 to 0.70), 0.31% (95% CI 0.08 to 0.54), and 0.30% (95% CI 0.10 to 0.50) higher HAA in White participants, respectively. No association was found in participants of other races/ethnicities. Smoking modified the association between B2GP1 isotypes and HAA: in individuals with moderate smoking history, every doubling of B2GP1 IgA, IgG and IgM was associated with 0.84% (95% CI 0.30 to 1.38), 0.97% (95% CI 0.43 to 1.52) and 0.65% (95% CI 0.11 to 1.20) higher HAA, respectively. There was no association between antiphospholipid antibodies and ILA.
conclusionsAntiphospholipid antibodies are associated with HAA, a quantitative measure of lung injury, inflammation and fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.